Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.53 and traded as high as $4.59. Cumberland Pharmaceuticals shares last traded at $4.40, with a volume of 118,912 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th.

Cumberland Pharmaceuticals Stock Down 4.1 %

The company has a market cap of $61.46 million, a P/E ratio of -5.71 and a beta of -0.18. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The firm has a fifty day moving average price of $4.38 and a 200 day moving average price of $2.53.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The company had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Institutional Trading of Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP boosted its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 37,649 shares of the specialty pharmaceutical company’s stock after buying an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. Institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.